Heart Failure with Preserved Ejection Fraction and Obstructive Sleep Apnea: A Novel Paradigm for Additional Cardiovascular Benefit of SGLT2 Inhibitors in Subjects With or Without Type 2 Diabetes-Reference-Cited by-同舟云学术

Heart Failure with Preserved Ejection Fraction and Obstructive Sleep Apnea: A Novel Paradigm for Additional Cardiovascular Benefit of SGLT2 Inhibitors in Subjects With or Without Type 2 Diabetes

Published:2022-09-16 Issue:11 Volume:39 Page:4837-4846
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Monda Vincenzo Maria,Gentile Sandro^ORCID,Porcellati Francesca,Satta Ersilia,Fucili Alessandro,Monesi Marcello,Strollo Felice

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12325-022-02310-2.pdf

Reference80 articles.

1. Somers VK, White DP, Amin R, et al.. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation. 2008;118(10):1080–111. https://doi.org/10.1161/CIRCULATIONAHA.107.189375 (Erratum in Circulation. 2009 Mar 31;119(12):e380).

2. Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective. Circ Res. 2019;124(11):1598–617. https://doi.org/10.1161/CIRCRESAHA.119.313572.

3. Trevisan L, Cautela J, Resseguier N, et al. Prevalence and characteristics of coronary artery disease in heart failure with preserved and mid-range ejection fractions: a systematic angiography approach. Arch Cardiovasc Dis. 2018;111(2):109–18. https://doi.org/10.1016/j.acvd.2017.05.006.

4. Mentz RJ, Kelly JP, von Lueder TG, et al. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 2014;64(21):2281–93. https://doi.org/10.1016/j.jacc.2014.08.036.

5. Unger ED, Dubin RF, Deo R, et al. Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail. 2016;18(1):103–12. https://doi.org/10.1002/ejhf.445.

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Type Disparity in Sodium–Glucose Cotransporter-2 Inhibitors in Incidences of Renal Cell Carcinoma: A Propensity-Score-Matched Cohort Study;Cancers;2024-06-05

2. Expert Opinion on Screening and Risk Stratification of Heart Diseases in Indian Women;Indian Journal of Clinical Cardiology;2024-05-30

3. Improving therapeutic outcomes in heart failure with reduced nonvalvular ejection fraction: A clinical study of heart failure education intervention;Clinical Cardiology;2024-04-29

4. Sleep-disordered breathing in heart failure;Current Opinion in Cardiology;2024-02-19

5. Heart failure with preserved ejection fraction risk is associated with prevalence and severity of obstructive sleep apnea;Journal of Clinical Sleep Medicine;2023-11-14